| Stereochemistry | ACHIRAL |
| Molecular Formula | C35H32N6O4 |
| Molecular Weight | 600.6664 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC2=CN=CC=C2N1CC3CCN(CC3)C(=O)\C=C(\C4=CC=CC=C4)C5=CC=C(C=C5)\N=N\C6=CC=C(O)C(=C6)C(O)=O
InChI
InChIKey=AYEAMZDTWLXZIJ-RKOUKRECSA-N
InChI=1S/C35H32N6O4/c1-23-37-31-21-36-16-13-32(31)41(23)22-24-14-17-40(18-15-24)34(43)20-29(25-5-3-2-4-6-25)26-7-9-27(10-8-26)38-39-28-11-12-33(42)30(19-28)35(44)45/h2-13,16,19-21,24,42H,14-15,17-18,22H2,1H3,(H,44,45)/b29-20-,39-38+
| Molecular Formula | C35H32N6O4 |
| Molecular Weight | 600.6664 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Optical Activity | NONE |
Dersalazine is a locally-acting compound. It is a potent platelet activating factor (PAF)-antagonist. Dersalazine inhibited IL-1beta or TNF-alpha production in THP-1 or U937 cells, respectively. Dersalazine sodium reduced colonic proinflammatory cytokines IL-1b, IL-6, and IL-17 in dextran sodium sulphate (DSS)–induced colitis. After oral administration, dersalazine sodium is mostly unabsorbed until it reaches the large bowel where the azo bond is reduced by bacteria releasing the active compound. Dersalazine had been in phase I clinical trial for the treatment of ulcerative colitis. No serious adverse reactions were detected in clinical trial. However, no recent development has been reported.
Approval Year
|
|
METABOLITE ACTIVE -> PRODRUG |
|
||
|
|
METABOLITE ACTIVE -> PRODRUG |
|
Showing 1 to 2 of 2 entries
|
|
ACTIVE MOIETY |
|
||
|
|
ACTIVE MOIETY |
|
Showing 1 to 2 of 2 entries